Department of Minimally Invasive Therapy Center, Fudan University Shanghai Cancer Center, Shanghai 200032, PR China; Department of Oncology, Shanghai Medical College, Fudan University, Shanghai 200032, PR China.
Department of Minimally Invasive Therapy Center, Fudan University Shanghai Cancer Center, Shanghai 200032, PR China; Department of Oncology, Shanghai Medical College, Fudan University, Shanghai 200032, PR China.
Biochim Biophys Acta Rev Cancer. 2020 Aug;1874(1):188385. doi: 10.1016/j.bbcan.2020.188385. Epub 2020 Jun 15.
As a promising area of tumor treatment, immunotherapies, such as immune checkpoint inhibitors, have been applied to various types of cancer. However, many patients do not respond to such therapies. Increasing application of tumor ablation therapy, a minimally invasive treatment, has been observed in the clinic. Although it can boost the anti-tumor immune response of patients in many ways, ablation alone is not sufficient to remove the tumor completely or stop tumor recurrence in the long term. Currently, there is emerging research focusing on ablation in combination with immunotherapy, aiming to confirm the therapeutic value of this treatment for cancer patients. Hence, in this article, we review the classification, guideline recommendations, and immunomodulatory effects of ablation therapy, as well as the pre-clinical and clinical research of this combination therapy.
作为肿瘤治疗的一个有前途的领域，免疫疗法，如免疫检查点抑制剂，已被应用于各种类型的癌症。然而，许多患者对这些治疗方法没有反应。在临床上，越来越多地应用肿瘤消融疗法，一种微创治疗方法。尽管它可以通过多种方式增强患者的抗肿瘤免疫反应，但单独消融不足以完全清除肿瘤或长期阻止肿瘤复发。目前，有越来越多的研究关注消融联合免疫治疗，旨在确定该治疗方法对癌症患者的治疗价值。因此，在本文中，我们回顾了消融治疗的分类、指南建议和免疫调节作用，以及该联合治疗的临床前和临床研究。
